NCT01336959终止2 期
A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 91
- 试验地点
- 1
- 主要终点
- Renal Function Measured at 48 Hours Post Cardiac Surgery With Cardiopulmonary Bypass Pump.
研究概览
简要总结
This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients scheduled for elective cardiac surgery with CPB. Allowable procedures are CABG alone, aortic valve replacement or repair alone, mitral valve replacement or repair alone, CABG with aortic valve replacement or repair, and CABG with mitral valve replacement or repair. Patients with repeat surgery for any of the procedures can be included.
- •Patients must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) 18 kg/m2
- •Have an eGFR ≥ 30 and ≤ 60 mL/min/1.73 m2 to participate in Part A, or an eGFR > 60 mL/min/1.73 m2 to participate in Part B. Upon completion of Part A, patients with eGFR ≥ 30 mL/min/1.73 m2 may participate in Part B, with dose administered as per the dosing table
排除标准
- •left ventricular ejection fraction, in the last 6 months, ≥30%
- •Active systemic infection or uncontrolled diabetes mellitus with a glucose ≥250 mg% at the screening assessment
- •Pregnant or nursing (lactating) women,
- •Female subjects must either:
- •have been surgically sterilized or hysterectomized at least 6 months prior to study participation, or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to study participation. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow- up hormone level assessment is she considered not of child bearing potential, Surgical sterilization procedures or hysterectomy must be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF, OR be postmenopausal. Female subjects are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). Female subjects 60 years of age or younger must confirm menopause by the demonstration of a plasma FSH level in the postmenopausal range according to the lab normal range. Documentation of a prior plasma FSH level is acceptable
- •History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of drug abuse as indicated by the laboratory assays conducted during screening or baseline
- •New cancer diagnosis with planned chemotherapy and/or radiation therapy, or cancer requiring ongoing chemotherapy and/or radiation therapy at the time of screening
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
Open Label - BCT197 Part A
Experimental
10mg single dose of BCT197
干预措施: BCT197 Part A (Drug)
BCT197 Part B
Experimental
Single dose of 50mg BCT197
干预措施: BCT197 Part B (Drug)
BCT 197 Placebo Part B
Placebo Comparator
Single dose of matching placebo to 50mg BCT197
干预措施: Placebo (Drug)
结局指标
主要结局
Renal Function Measured at 48 Hours Post Cardiac Surgery With Cardiopulmonary Bypass Pump.
时间窗: 48 hours
Median percent change from baseline in estimated Glomerular Filtration Rate (eGFR) at 48 hours postdose.
次要结局
- Pharmacokinetic Measurements of Drug in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass Pump. Pharmacokinetics Will be Measured Using Cmax(4 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac SurgeryAcute Kidney InjuryNCT01777165AbbVie240
已完成
2 期
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationChronic Obstructive Pulmonary DiseaseNCT01332097Mereo BioPharma183
终止
2 期
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk SurgeryCardiothoracic SurgeryVascular SurgeryNCT01897519AbbVie56
已完成
不适用
Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes PatientsType 2 DiabetesNCT04673656BioKier Inc.60
已完成
2 期
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02700919Mereo BioPharma282